--- topic: "Probiotics" title: "Strains That Matter" order: 2 description: "Which probiotic strains are backed by evidence for specific health conditions" question: "Which probiotic strains have real evidence for diarrhea and IBS?" answer: "Saccharomyces boulardii and Lactobacillus rhamnosus GG probably prevent antibiotic-associated diarrhea and shorten acute diarrhea; evidence for IBS strains is thinner." actions: - "Choose by strain, not just species: check the label for the exact strain, because results from one strain do not carry over to others." - "For diarrhea (antibiotic-associated or acute), look for Saccharomyces boulardii or Lactobacillus rhamnosus GG [1][3]; across all strains, probiotics shortened acute infectious diarrhea by roughly a day, mostly in children [2]." - "For IBS, the strain with trial support is Bifidobacterium longum 35624, tested over 8 weeks [5]." cautions: - "IBS evidence for B. longum 35624 rests mainly on one 8-week trial, and the celiac finding on one study of 109 people [4][5]." - "Not a substitute for medical care if diarrhea or digestive symptoms persist." confidence: 4 confidenceNote: "A 31-trial Cochrane review (8,672 people) and a 63-trial meta-analysis support diarrhea use; IBS and celiac findings come from single trials." evidenceSummary: rctCount: 1 observationalCount: 0 metaAnalysisCount: 3 totalParticipants: "16,000+" replicated: true newestStudyYear: 2019 references: - id: "1" pmid: "29257353" title: "Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children" authors: "Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, Johnston BC" year: 2017 journal: "Cochrane Database of Systematic Reviews" - id: "2" pmid: "21069673" title: "Probiotics for treating acute infectious diarrhoea" authors: "Allen SJ, Martinez EG, Gregorio GV, Dans LF" year: 2010 journal: "Cochrane Database of Systematic Reviews" - id: "3" pmid: "20458757" title: "Systematic review and meta-analysis of Saccharomyces boulardii in adult patients" authors: "McFarland LV" year: 2010 journal: "World Journal of Gastroenterology" - id: "4" pmid: "29688915" title: "Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial" authors: "Francavilla R, Piccolo M, Francavilla A, Polimeno L, Semeraro F, Cristofori F, Castellaneta S, Barone M, Indrio F, Gobbetti M, De Angelis M" year: 2019 journal: "Journal of Clinical Gastroenterology" - id: "5" pmid: "15765388" title: "Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles" authors: "O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EMM" year: 2005 journal: "Gastroenterology" --- Not all probiotics are the same. Different bacterial strains have different effects, and a strain that helps with diarrhea may do nothing for bloating. The most studied genera are Lactobacillus, Bifidobacterium, and the yeast Saccharomyces boulardii. Choosing the right strain for the right problem is what makes probiotics actually useful [1]. Probiotic benefits are strain-specific, meaning results from one strain cannot be generalized to others even within the same species. Here are the best-supported strains for common conditions: **Antibiotic-associated diarrhea:** Saccharomyces boulardii (a beneficial yeast, not a bacterium) has the strongest evidence for preventing diarrhea caused by antibiotics, including Clostridium difficile infection. A Cochrane review found that probiotics reduced the risk of C. difficile-associated diarrhea by about 60% when given alongside antibiotics [1]. Lactobacillus rhamnosus GG is another well-supported strain for this use [2]. **Irritable bowel syndrome (IBS):** Bifidobacterium longum 35624 (also marketed as Bifidobacterium infantis 35624) has shown the ability to reduce bloating, abdominal pain, and bowel irregularity in IBS patients. Importantly, it also normalized the ratio of anti-inflammatory to pro-inflammatory cytokines, suggesting a genuine immunomodulatory mechanism rather than just symptom masking [5]. **Acute infectious diarrhea:** A Cochrane meta-analysis of 63 trials, 56 of them in infants and young children, found that probiotics reduced the mean duration of acute infectious diarrhea by roughly one day (24.76 hours), although the size of the effect varied considerably between studies and was not explained by the probiotic strain [2]. **Multi-strain formulations:** Some conditions may respond better to combinations of strains. Francavilla et al. (2019) showed that a multispecies probiotic improved persistent GI symptoms in celiac patients already on a gluten-free diet, where single-strain approaches had been less effective [4]. The Cochrane review by Goldenberg et al. analyzed 31 randomized controlled trials (8,672 participants) examining probiotics for C. difficile-associated diarrhea. The pooled analysis showed a significant risk reduction (RR 0.40, 95% CI 0.30 to 0.52) for C. difficile-associated diarrhea when probiotics were co-administered with antibiotics. S. boulardii and L. rhamnosus GG were the most frequently studied strains with positive outcomes. The number needed to treat was 33 for moderate-risk populations and 12 for high-risk populations [1]. Allen et al. (2010) conducted a Cochrane meta-analysis of 63 trials covering 8,014 participants examining probiotics for acute infectious diarrhea; 56 of the trials recruited infants and young children. Probiotics reduced the mean duration of diarrhea by 24.76 hours (95% CI 15.9 to 33.6 hours; 35 trials, 4,555 participants), although the size of the effect varied considerably between studies. The differences in effect size were not explained by study quality, probiotic strain, dosage of organisms, or the cause or severity of the diarrhea, and the authors concluded that more research is needed to guide the use of particular probiotic regimens in specific patient groups [2]. McFarland (2010) reviewed the evidence for Saccharomyces boulardii across multiple gastrointestinal indications. This probiotic yeast is notable because it is naturally resistant to antibiotics, making it particularly suitable for use during antibiotic therapy. The review found positive evidence for prevention of antibiotic-associated diarrhea (RR 0.47, 95% CI 0.35 to 0.63), traveler's diarrhea, and recurrent C. difficile infection. S. boulardii exerts its effects through multiple mechanisms including secretion of a protease that degrades C. difficile toxin A and stimulation of secretory IgA [3]. O'Mahony et al. (2005) conducted a randomized controlled trial comparing B. longum 35624, L. salivarius UCC4331, and placebo in IBS patients over 8 weeks. Only B. longum 35624 significantly reduced composite IBS symptom scores. Critically, this strain also normalized the IL-10/IL-12 cytokine ratio, which was abnormally skewed toward the pro-inflammatory IL-12 at baseline. This finding provided mechanistic evidence that certain probiotic strains can modulate systemic immune responses, not just local gut effects [5]. Francavilla et al. (2019) studied 109 celiac patients with persistent IBS-type symptoms despite adherence to a gluten-free diet. A 6-week course of a multispecies probiotic (containing Lactobacillus and Bifidobacterium strains) significantly reduced IBS Severity Scoring System scores and was associated with shifts in fecal microbiota composition, including increased Bifidobacterium counts. This study is notable because it demonstrates probiotic efficacy in a population where residual gut dysbiosis persists despite dietary treatment of the primary condition [4].